BCL2L14 and colorectal cancer: We found that both BCL-G splice variants — BCL-GS (short) and BCL-GL (long) — were highly expressed in healthy gut tissue, and that their mRNA levels decreased in active inflammatory bowel diseases (for BCL-GS) and colorectal cancer (for BCL-GS/L).